You are here: Industry Insights > CV

News List

Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction drugs.com
February 04, 2022
Federal health officials announced Friday that they are expanding nationwide efforts to track COVID-19 by monitoring virus levels found in raw sewage.
Farxiga Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction americanpharmaceuticalreview
July 24, 2020
AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction ...
MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes trial pharmatimes
June 22, 2020
MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety of their diabetes drug Steglatro (ertugliflozin).
AstraZeneca’s heart disease drug Brilinta gets FDA approval pharmaceutical-technology
June 02, 2020
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Brilinta (ticagrelor) to decrease the risk of a first heart attack or stroke in high-risk patients suffering from coronary artery disease (CAD).
AZ to take $100m hit from ending trial of CV drug Epanova pharmaceutical-technology
January 15, 2020
AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation by an Independent Data Monitory Committee that the drug was unlikely to demonstrate cardiovascular (CV) benefit
CV Risk Lower With Metformin in T2DM + Reduced Kidney Function drugs
September 20, 2019
According to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes ...
Linagliptin Noninferior for CV Risk in Early Type 2 Diabetes drugs
September 20, 2019
According to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes ...
Retinal Vein Occlusion Linked to Higher Risk for CV Events drugs
September 10, 2019
Retinal vein occlusion (RVO) is associated with an increased risk for cardiovascular events and all-cause mortality, according to a review published in the September issue of Retina.
Metabolic Surgery May Reduce CV Risk in T2DM With Obesity drugs
September 05, 2019
For patients with type 2 diabetes and obesity, metabolic surgery is associated with a reduced risk for mortality and major adverse cardiovascular events...
LV Hypertrophy Predicts Long-Term Risk for CV Events drugs
August 28, 2019
Elevated left ventricular (LV) mass is associated with an increased long-term risk for cardiovascular (CV) events, according to a study published online Aug. 27 in Radiology.

Previous page 1 2 3 Next page